JPS6251933B2 - - Google Patents
Info
- Publication number
- JPS6251933B2 JPS6251933B2 JP16377281A JP16377281A JPS6251933B2 JP S6251933 B2 JPS6251933 B2 JP S6251933B2 JP 16377281 A JP16377281 A JP 16377281A JP 16377281 A JP16377281 A JP 16377281A JP S6251933 B2 JPS6251933 B2 JP S6251933B2
- Authority
- JP
- Japan
- Prior art keywords
- pressure
- sensitive adhesive
- therapeutic
- adhesive layer
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】
本発明は皮膚疾患の治療、消炎、鎮痛等に適し
た治療用接着テープもしくはシートに関する。薬
物を経皮吸収させるのに、皮膚の角質層の含水率
を高くすると、毛包―脂線系だけでなく角質層を
直接通る吸収路も利用できるので、効果的な皮膚
吸収を行わせることができる。このため、皮膚疾
患の治療として、最近、皮膚に軟膏等の外用薬を
塗りこの上をフイルムで覆い効果的な薬剤の吸収
をはかる密封包帯療法（ODT療法）が普及して
いる。しかし、この密封包帯療法は患部へのフイ
ルムの取付が面倒であるばかりでなく、嵩張るこ
と、剥れ易いこと、患部の面積が大きい場合或は
患部の形状が複雑な場合に患部へ密着しにくいこ
と等の欠点があつた。これらの欠点をなくすた
め、基材の片面に薬剤を含む感圧性接着剤層が設
けられた治療用テープが市販されている。しか
し、このような治療用テープを長時間保存する間
に、感圧性接着剤層に含まれる薬剤の皮膚への移
行性が経時的に悪くなり、又薬剤が変化して初期
の含有薬物以外のものが皮膚へ移行したりして治
療効果を著しく低下させるという欠点を有してい
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a therapeutic adhesive tape or sheet suitable for treating skin diseases, anti-inflammatory, analgesic, etc. For transdermal absorption of drugs, increasing the water content of the stratum corneum of the skin allows for effective absorption by using not only the hair follicle-sebaceous system but also the absorption route that passes directly through the stratum corneum. Can be done. Therefore, as a treatment for skin diseases, occlusive dressing therapy (ODT therapy), which involves applying an external medicine such as an ointment to the skin and covering it with a film to effectively absorb the medicine, has recently become popular. However, with this occlusive bandage therapy, not only is it troublesome to attach the film to the affected area, but it is also bulky, easily peels off, and difficult to adhere to the affected area when the area of the affected area is large or the shape of the affected area is complex. There were some drawbacks. To overcome these drawbacks, therapeutic tapes are commercially available which have a pressure-sensitive adhesive layer containing a drug on one side of the substrate. However, while such therapeutic tapes are stored for long periods of time, the transfer of the drugs contained in the pressure-sensitive adhesive layer to the skin deteriorates over time, and the drugs change, resulting in drugs other than the initially contained drugs. It has the disadvantage that substances may migrate into the skin, significantly reducing the therapeutic effect.
本発明の目的は上記の欠点を解消し、長期間の
保存によつても感圧性接着剤層に含まれる薬剤が
変化せず、薬剤が常時効率よく皮膚へ移行され、
安定した治療効果を発揮しうる。治療用接着テー
プもしくはシートを提供することを目的とする。 The object of the present invention is to eliminate the above-mentioned drawbacks, and to ensure that the drug contained in the pressure-sensitive adhesive layer does not change even during long-term storage, and that the drug is constantly and efficiently transferred to the skin.
It can exhibit stable therapeutic effects. The purpose is to provide therapeutic adhesive tapes or sheets.
本発明の要旨は、基材の片面に、副腎皮質ホル
モン系薬剤を含むアクリル系感圧性接着剤層が設
けられている治療用接着テープもしくはシートに
おいて、上記感圧性接着層には感圧性接着剤100
重量部当り金属塩化物が0.1乃至20重量部含有さ
れていることを特徴とする治療用接着テープもし
くはシートに存する。 The gist of the present invention is a therapeutic adhesive tape or sheet in which an acrylic pressure-sensitive adhesive layer containing a corticosteroid drug is provided on one side of a base material, wherein the pressure-sensitive adhesive layer includes a pressure-sensitive adhesive. 100
The present invention relates to a therapeutic adhesive tape or sheet containing 0.1 to 20 parts by weight of metal chloride per part by weight.
次に本発明治療用接着テープもしくはシートに
ついて更に詳細に説明する。 Next, the therapeutic adhesive tape or sheet of the present invention will be explained in more detail.
本発明に用いられる基材としては、ポリエチレ
ン、ポリプロピレン、エチレン―酢酸ビニル共重
合体、軟質ポリ塩化ビニル、セロハン等の可焼性
を有するフイルムもしくはシート、又はこれらの
表面をコロナ放電等で処理したもの等が好適に使
用される。基材の厚みとしては、50〜100ミクロ
ンの範囲が好ましい。 The base material used in the present invention is a flammable film or sheet such as polyethylene, polypropylene, ethylene-vinyl acetate copolymer, soft polyvinyl chloride, or cellophane, or a film or sheet whose surface has been treated with corona discharge, etc. etc. are preferably used. The thickness of the base material is preferably in the range of 50 to 100 microns.
前記基材の片面に、アクリル系感圧性接着剤層
が設けられる。この感圧性接着剤としては、２―
エチルヘキシルアクリレート、ブチルアクリレー
トやその他のアクリル酸エステル又はメタクリル
酸エステルの重合体か、又はこれらのアクリル系
単量体が主体を占める他の単量体との共重合体が
使用される。感圧性接着剤層中には治療用薬剤が
含有される。かゝる薬剤としては例えばヒドロコ
ルチゾン、酢酸ヒドロコルチゾン、プレドニゾロ
ン、デキサメタゾン、ペタメタゾン、フルオシノ
ロンアセトニド等の副腎皮質ホルモンが使用され
る。 An acrylic pressure-sensitive adhesive layer is provided on one side of the base material. As this pressure sensitive adhesive, 2-
Polymers of ethylhexyl acrylate, butyl acrylate, and other acrylic esters or methacrylic esters, or copolymers of these acrylic monomers with other monomers are used. A therapeutic agent is contained within the pressure sensitive adhesive layer. Examples of such drugs include adrenocortical hormones such as hydrocortisone, hydrocortisone acetate, prednisolone, dexamethasone, petamethasone, and fluocinolone acetonide.
感圧性接着剤中に含有される薬剤の量としては
感圧性接着剤層の厚み、薬剤の種類等により異な
るが、感圧性接着剤層１cm2当り１μｇ〜５mgの範
囲が好ましい。 The amount of the drug contained in the pressure-sensitive adhesive varies depending on the thickness of the pressure-sensitive adhesive layer, the type of drug, etc., but is preferably in the range of 1 μg to 5 mg per 1 cm 2 of the pressure-sensitive adhesive layer.
ところで上記の感圧性接着剤層中における薬剤
は、感圧性接着剤を構成するポリマーや、残存モ
ノマー、感圧性接着剤層中に必要に応じて添加さ
れる粘着性付与剤、架橋剤、その他の添加剤との
相互作用により経時的に変化し、感圧性接着剤層
からの薬剤の皮膚への移行性を低下させることが
あり、又変化した薬剤が皮膚へ移行されるような
ことがあり、治療効果の低下をもたらす。そこで
本発明においては、感圧性接着剤層に、感圧性接
着剤100重量部当り金属塩化物が0.1乃至20重量部
含有される。金属塩化物としては、例えばマグネ
シウム、カルシウム、亜鉛、ナトリウム等の塩化
物、これらの塩化物の水和物が好適である。 By the way, the chemicals in the pressure-sensitive adhesive layer mentioned above include the polymer constituting the pressure-sensitive adhesive, residual monomers, tackifiers, cross-linking agents, and other substances added as necessary to the pressure-sensitive adhesive layer. It may change over time due to interaction with additives, reducing the transferability of the drug from the pressure-sensitive adhesive layer to the skin, and the changed drug may also be transferred to the skin. This results in a decrease in therapeutic efficacy. Therefore, in the present invention, the pressure-sensitive adhesive layer contains 0.1 to 20 parts by weight of metal chloride per 100 parts by weight of the pressure-sensitive adhesive. As the metal chloride, for example, chlorides of magnesium, calcium, zinc, sodium, etc., and hydrates of these chlorides are suitable.
金属塩化物を前記量使用する場合には、薬剤が
感圧性接着剤層から皮膚へ効率よく移行し、かつ
その移行性が経時的に変化せず安定したものとな
る。この場合における金属塩化物の作用は、薬剤
の官能基に配位して感圧性接着剤の主成分である
ポリマーや、残存モノマー、粘着性付与剤、架橋
剤その他の添加剤との相互作用を阻害し、その結
果感圧性接着剤層から皮膚への薬剤の移行性を安
定させるものと推測される。 When the metal chloride is used in the above amount, the drug is efficiently transferred from the pressure-sensitive adhesive layer to the skin, and the transferability thereof does not change over time and is stable. In this case, the action of the metal chloride is to coordinate with the functional group of the drug and prevent interaction with the polymer, which is the main component of the pressure-sensitive adhesive, residual monomers, tackifiers, crosslinkers, and other additives. It is presumed that this inhibits the transfer of the drug from the pressure-sensitive adhesive layer to the skin, thereby stabilizing the transfer of the drug from the pressure-sensitive adhesive layer to the skin.
金属塩化物による前記の効果は、薬剤が水酸基
もしくはカルボキシル基を有する場合において著
しいものとなる。 The above-mentioned effects of metal chlorides become remarkable when the drug has a hydroxyl group or a carboxyl group.
本発明治療用接着テープもしくはシートは、上
記の構成とされているので、感圧性接着剤層中に
含まれる薬剤が効率よく皮膚に移行するとともに
その移行性が経時的に変化せず、常に安定した治
療効果を有するものとなる。 Since the therapeutic adhesive tape or sheet of the present invention has the above-mentioned structure, the drug contained in the pressure-sensitive adhesive layer efficiently transfers to the skin, and its transferability does not change over time and is always stable. It has a therapeutic effect.
以下本発明を実施例により説明する。実施例中
に単に部とあるのは重量部である。 The present invention will be explained below with reference to Examples. In the examples, "parts" simply refer to parts by weight.
実施例 １
撹拌装置、温度計、冷却管及び窒素導入管の備
えつけられたセパラブルフラスコに２―エチルヘ
キシルアクリレート80部、ブチルアクリレート15
部、アクリル酸５部、酢酸エチル100部、重合開
始剤として過酸化ベンゾイル0.3部を仕込み、窒
素気流下で60℃で18時間重合し粘度6000センチポ
イズ（25℃）の共重合体を得た。この共重合体
100部に対し、別に調整した酢酸マグネシウム溶
液（重量比で酢酸マグネシウム４水和物：メタノ
ール＝１：９）3.5部及び塩化カルシウム溶液
（重量比で塩化カルシウム：メタノール＝１：
９）20部及びプレドニゾロン溶液（重量比でプレ
ドニゾロン：メタノール＝１：49）15部を加えて
よく混合した後、60μｍのポリエチレンフイル上
に塗布し、80℃で20分間乾燥して厚さ50μｍの感
圧性接着剤層を得た。なお、プレドニゾロンは上
記厚みにおいて30μｇ／cm2となるように配合し
た。次いでこれをテープ状に裁断した。Example 1 80 parts of 2-ethylhexyl acrylate and 15 parts of butyl acrylate were placed in a separable flask equipped with a stirrer, a thermometer, a cooling tube, and a nitrogen introduction tube.
1 part, 5 parts of acrylic acid, 100 parts of ethyl acetate, and 0.3 part of benzoyl peroxide as a polymerization initiator were charged, and polymerization was carried out at 60°C for 18 hours under a nitrogen stream to obtain a copolymer with a viscosity of 6000 centipoise (25°C). This copolymer
To 100 parts, 3.5 parts of a separately prepared magnesium acetate solution (magnesium acetate tetrahydrate:methanol = 1:9 by weight) and calcium chloride solution (calcium chloride:methanol = 1:9 by weight).
9) Add 20 parts and 15 parts of prednisolone solution (prednisolone:methanol = 1:49 by weight), mix well, apply on a 60 μm polyethylene film, dry at 80°C for 20 minutes, and make a 50 μm thick film. A pressure sensitive adhesive layer was obtained. In addition, prednisolone was blended so that it would be 30 μg/cm 2 at the above thickness. This was then cut into tape shapes.
かくして得られた治療用テープを60℃で100日
間放置した後、水に24時間浸漬し、抽出されたプ
レドニゾロン量を高速液体クロマトグラフにより
242nmの波長で定量したところ、プレドニゾロン
は初期含有量に対し92重量％が抽出され、又プレ
ドニゾロン以外のピークは認められなかつた。 The therapeutic tape thus obtained was left at 60°C for 100 days, then immersed in water for 24 hours, and the amount of prednisolone extracted was measured using high-performance liquid chromatography.
When quantified at a wavelength of 242 nm, 92% by weight of prednisolone was extracted based on the initial content, and no peaks other than prednisolone were observed.
比較例
実施例１において塩化カルシウムを含まないも
のとする以外は実施例１と同様にして治療用テー
プを作成した。Comparative Example A therapeutic tape was prepared in the same manner as in Example 1 except that it did not contain calcium chloride.
次いで実施例１と同様にしてプレドニゾロンを
高速液体クロマトグラフにより定量したところ、
10重量％のプレドニゾロンしか抽出されずプレド
ニゾロンが反応して得られた生成物と推定される
ピークが認められた。 Next, prednisolone was quantified by high performance liquid chromatography in the same manner as in Example 1.
Only 10% by weight of prednisolone was extracted, and a peak presumed to be a product obtained by reaction of prednisolone was observed.
Claims (1)
むアクリル系感圧性接着剤層が設けられている治
療用接着テープもしくはシートにおいて、上記感
圧性接着剤層には感圧性接着剤100重量部当り金
属塩化物が0.1乃至20重量部含有されていること
を特徴とする治療用接着テープもしくはシート。 ２ 金属塩化物が塩化マグネシウムである、特許
請求の範囲第１項記載の治療用接着テープもしく
はシート。 ３ 金属塩化物が塩化カルシウムである、特許請
求の範囲第１項記載の治療用接着テープもしくは
シート。 ４ 金属塩化物が塩化亜鉛である、特許請求の範
囲第１項記載の治療用接着テープもしくはシー
ト。[Scope of Claims] 1. A therapeutic adhesive tape or sheet in which an acrylic pressure-sensitive adhesive layer containing a corticosteroid drug is provided on one side of a base material, wherein the pressure-sensitive adhesive layer has a pressure-sensitive adhesive layer. A therapeutic adhesive tape or sheet containing 0.1 to 20 parts by weight of metal chloride per 100 parts by weight of adhesive. 2. The therapeutic adhesive tape or sheet according to claim 1, wherein the metal chloride is magnesium chloride. 3. The therapeutic adhesive tape or sheet according to claim 1, wherein the metal chloride is calcium chloride. 4. The therapeutic adhesive tape or sheet according to claim 1, wherein the metal chloride is zinc chloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16377281A JPS5865168A (en) | 1981-10-13 | 1981-10-13 | Adhesive tape or sheet for treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16377281A JPS5865168A (en) | 1981-10-13 | 1981-10-13 | Adhesive tape or sheet for treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5865168A JPS5865168A (en) | 1983-04-18 |
| JPS6251933B2 true JPS6251933B2 (en) | 1987-11-02 |
Family
ID=15780419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16377281A Granted JPS5865168A (en) | 1981-10-13 | 1981-10-13 | Adhesive tape or sheet for treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5865168A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9370495B2 (en) | 2010-02-24 | 2016-06-21 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011105492A1 (en) * | 2010-02-24 | 2011-09-01 | 久光製薬株式会社 | Transdermal preparation |
-
1981
- 1981-10-13 JP JP16377281A patent/JPS5865168A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9370495B2 (en) | 2010-02-24 | 2016-06-21 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5865168A (en) | 1983-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0474329B2 (en) | ||
| JPH0499720A (en) | Medicinal pharmaceutical for percutaneous administration | |
| JPH02270818A (en) | Patch comprising polyurethane film as substrate | |
| JPS6251933B2 (en) | ||
| CN112826809B (en) | Stable tulobuterol percutaneous absorption preparation | |
| CN100508964C (en) | Plaster and its preparation method | |
| JPS632533B2 (en) | ||
| JP4988079B2 (en) | Transdermal preparation | |
| JPS597689B2 (en) | pharmaceutical formulations | |
| JPS6320410B2 (en) | ||
| JP2000026285A (en) | Plaster | |
| JPS6066759A (en) | Pharmaceutical preparation | |
| JPS6221395B2 (en) | ||
| JPH0339488B2 (en) | ||
| JPH0335284B2 (en) | ||
| JP3207257B2 (en) | Patch | |
| JP3046330B2 (en) | Patch preparation | |
| JP3233705B2 (en) | Patch | |
| JPS6221394B2 (en) | ||
| JP3525225B2 (en) | Eperisone or tolperisone transdermal absorption tape or patch, and method for producing the same | |
| JPS62112557A (en) | Patch agent for external application | |
| JPS5812255B2 (en) | Treatment adhesive tape or sheet | |
| JPS58138462A (en) | Adhesive tape or sheet ror treatment | |
| JPH1179980A (en) | Transdermal formulation | |
| JPS5827247B2 (en) | Treatment adhesive tape or sheet |